AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 08/03/23

2023-08-03 14:20:38 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is $0.10 (-47.4% Y/Y) and the consensus Revenue Estimate is $565.11M (+1.1% Y/Y). Over the la...

- Represents three high-value medicines across complex dosage forms Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Adm...

2023-07-10 08:00:00 ET Summary A Complete Response Letter from the FDA temporarily tanked AMRX stock. New launches and established products should contribute to Amneal Pharmaceuticals' Q2 growth. A generic to blockbuster sets Amneal up nicely for Q3 and onward. July ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on Aug...

2023-07-05 13:23:58 ET Shares of Amneal Pharmaceuticals (NYSE: AMRX) were down more than 13% as of 12:45 p.m. ET on Wednesday after the pharmaceutical company announced both positive and negative news regarding its clinical pipeline. The stock is still up more than 30% this year...

2023-07-05 10:02:39 ET Gainers: Impel Pharmaceuticals ( IMPL ) +32% . Adicet Bio ( ACET ) +18% . C4 Therapeutics ( CCCC ) +17% . NLS Pharmaceutics ( NLSP ) +7% . Poseida Therapeutics ( PSTX ) +4% . Losers: Amneal Pharmaceu...

2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...

2023-07-03 14:34:31 ET The US FDA has issued a Complete Response Letter to Amneal Pharmaceuticals ( NYSE: AMRX ) for Parkinson's disease candidate IPX203. The stock is down ~5% in after-hours trading Monday. The agency said that an adequate scientific bridge was not es...

- Launches authorized generic for Xyrem ® (sodium oxybate) in the U.S., representing another new complex generic product launch - Receives U.S. FDA approval for five new complex generics in the second quarter - Remains on track to deliver more than 30 new generic launch...

- Letter requests additional pharmacokinetic data - No clinical efficacy or manufacturing issues identified Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from t...